# OnCo record nct07162883 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07162883/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07162883", "NCT07162883" ;
  schema:name "Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)"@en ;
  schema:description "A phase 3 trial of QL2107 and pembrolizumab in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07162883/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07162883> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ql2107/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/qilu-pharmaceutical/> .